Source: davit kirakosyan
Bernstein SocGen Group Maintains Outperform Rating on Gilead Sciences
Bernstein SocGen Group, a leading financial services company, recently reiterated its Outperform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $135. This statement comes after careful consideration of the company’s financial exposure to recent Medicaid pricing changes.
As part of their evaluation, Bernstein highlighted that Gilead’s financial risk is limited due to the nature of the Medicaid pricing changes. According to the firm, only certain products from Gilead’s portfolio are aligning with the Most Favored Nation (MFN) pricing for Medicaid. This implies that a significant portion of the company’s product range remains unaffected.
Understanding the Impact on Gilead’s Portfolio
The firm’s analysis indicates that approximately 60% of Gilead’s portfolio would align with the MFN pricing model. After holding discussions with Gilead, Bernstein confirmed that the primary products affected by these changes are Genvoya and Odefsey. These two drugs together generated an estimated $750 million in Medicaid gross spend in 2023.
The MFN pricing model is a tool used by the US government to ensure that it pays the lowest price offered to any customer for a product. This policy aims to prevent suppliers, such as pharmaceutical companies, from charging higher prices to the government than they do to other customers.
For Gilead, this change in pricing means that the revenue generated from Genvoya and Odefsey will likely be affected. However, Bernstein’s report suggests that this impact will be limited and manageable for the company.
Alleviating Concerns Around Medicaid Pricing Risk
According to Bernstein, this confirmation of the limited exposure of Gilead’s product range to MFN pricing has alleviated concerns around the Medicaid pricing risk for Biktarvy, a key product in the company’s portfolio. Bernstein had previously expressed uncertainty regarding the potential impact of MFN pricing on this drug.
As per the firm’s analysis, the negotiations around MFN pricing have resulted in a favorable outcome for Gilead. The firm’s estimates indicate that the revenue impact for Gilead by 2026 should be minimal. They predict a loss of less than $200 million for Genvoya and Odefsey combined. This represents a low single-digit percentage range for the company’s overall revenue.
Looking Ahead: Implications for Gilead
The recent Medicaid pricing changes and the move towards MFN pricing for certain drugs have created uncertainty for many pharmaceutical companies. However, according to Bernstein SocGen Group, Gilead Sciences seems to be well-positioned to manage these changes.
The firm’s Outperform rating signals confidence in Gilead’s ability to navigate this challenging environment and continue to generate strong returns. The limited impact on key products like Biktarvy also suggests that Gilead’s main revenue streams are secure, despite potential changes in the pricing of Genvoya and Odefsey.
In conclusion, while the recent Medicaid pricing changes may present some challenges for pharmaceutical companies, Bernstein SocGen Group’s analysis indicates that Gilead Sciences is well-equipped to handle them. As such, their reaffirmation of an Outperform rating and $135 price target for the company should provide reassurance to investors.